<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作為您在 Google 上的首選新聞來源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>幾隻生物科技和醫療保健股票在週五的盤後交易中顯著上漲，受監管動態、融資更新和投資者情緒的推動。</p>
<p>Atossa Therapeutics, Inc. (ATOS) 上漲 12.98% 至 $0.69，漲幅 $0.080，因其宣佈美國食品藥品監督管理局孤兒藥品發展辦公室已授予 (Z)-endoxifen 用於杜氏肌營養不良症的孤兒藥資格。這一資格標誌着公司管線的一個重要里程碑。</p>
<p>ImmunityBio, Inc. (IBRX) 上漲 9.43% 至 $6.04，漲幅 $0.52。該公司報告稱，其註冊試驗 QUILT-2.005 針對 BCG 初治非肌肉侵襲性膀胱癌的入組超出預期，超過 85% 的研究人羣已入組。預計到 2026 年第二季度完成全部入組，並計劃在 2026 年底向 FDA 提交生物製品許可申請。</p>
<p>Femasys Inc. (FEMY) 上漲 10.68% 至 $0.72，漲幅 $0.070。該公司在 1 月 14 日披露，納斯達克批准其請求，給予額外 180 天的延長期限，以恢復符合最低$1.00 的出價要求。Femasys 現在有直到 2026 年 7 月 13 日的時間來滿足上市標準。</p>
<p>Foghorn Therapeutics Inc. (FHTX) 上漲 4.02% 至 $6.26，漲幅 $0.24。該公司宣佈以 30% 的溢價完成 5000 萬美元的註冊直接融資。此次發行包括普通股、預先融資的認股權證和按發行價格倍數定價的系列認股權證，毛收益總計約 5000 萬美元。</p>
<p>Daré Bioscience, Inc. (DARE) 小幅上漲 1.04% 至 $1.95，漲幅 $0.020。該公司週五沒有發佈任何新聞，但股票仍在盤後交易中小幅上漲。</p>
<p>Theravance Biopharma, Inc. (TBPH) 上漲 5.00% 至 $21.01，漲幅 $1.00。與 Daré類似，該公司週五沒有新聞，但股票在延長交易中上漲。</p>
<p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
<p>商業新聞</p>

標普生物技術 3 倍做空 - Direxion

FHTX

生物科技 ETF - VanEck Vectors

<p>幾隻生物科技和醫療股在週五的盤後交易中出現顯著上漲，受到監管更新和投資者情緒的影響。Atossa Therapeutics (ATOS) 上漲 12.98%，至 0.69 美元，此前獲得了 FDA 的孤兒藥資格認證。ImmunityBio (IBRX) 上漲 9.43%，至 6.04 美元，因試驗招募強勁。Femasys (FEMY) 上漲 10.68%，至 0.72 美元，因獲得合規延期。Foghorn Therapeutics (FHTX) 在獲得 5000 萬美元融資後上漲 4.02%，至 6.26 美元。儘管沒有新公告，Daré Bioscience (DARE) 和 Theravance Biopharma (TBPH) 也小幅上漲</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作為您在 Google 上的首選新聞來源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Several biotech and healthcare stocks posted notable gains in after-hours trading on Friday, driven by regulatory developments, financing updates, and investor sentiment.</p>
<div class="lb-trans"><p>幾隻生物科技和醫療保健股票在週五的盤後交易中顯著上漲，受監管動態、融資更新和投資者情緒的推動。</p>
</div><p>Atossa Therapeutics, Inc. (ATOS) rose 12.98% to $0.69, up $0.080 after announcing that the U.S. Food and Drug Administration's Office of Orphan Products Development granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy. The designation marks a significant milestone for the company's pipeline.</p>
<div class="lb-trans"><p>Atossa Therapeutics, Inc. (ATOS) 上漲 12.98% 至 $0.69，漲幅 $0.080，因其宣佈美國食品藥品監督管理局孤兒藥品發展辦公室已授予 (Z)-endoxifen 用於杜氏肌營養不良症的孤兒藥資格。這一資格標誌着公司管線的一個重要里程碑。</p>
</div><p>ImmunityBio, Inc. (IBRX) advanced 9.43% to $6.04, gaining $0.52. The company reported that enrollment in its registrational trial QUILT-2.005 for BCG-naïve non-muscle-invasive bladder cancer has surpassed expectations, with more than 85% of the study population enrolled. Full enrollment is anticipated by the second quarter of 2026, with a biologics license application submission to the FDA targeted by year end 2026.</p>
<div class="lb-trans"><p>ImmunityBio, Inc. (IBRX) 上漲 9.43% 至 $6.04，漲幅 $0.52。該公司報告稱，其註冊試驗 QUILT-2.005 針對 BCG 初治非肌肉侵襲性膀胱癌的入組超出預期，超過 85% 的研究人羣已入組。預計到 2026 年第二季度完成全部入組，並計劃在 2026 年底向 FDA 提交生物製品許可申請。</p>
</div><p>Femasys Inc. (FEMY) climbed 10.68% to $0.72, up $0.070. On January 14, the company disclosed that Nasdaq approved its request for an additional 180-day extension to regain compliance with the minimum $1.00 bid price requirement. Femasys now has until July 13, 2026 to meet the listing standard.</p>
<div class="lb-trans"><p>Femasys Inc. (FEMY) 上漲 10.68% 至 $0.72，漲幅 $0.070。該公司在 1 月 14 日披露，納斯達克批准其請求，給予額外 180 天的延長期限，以恢復符合最低$1.00 的出價要求。Femasys 現在有直到 2026 年 7 月 13 日的時間來滿足上市標準。</p>
</div><p>Foghorn Therapeutics Inc. (FHTX) gained 4.02% to $6.26, adding $0.24. The company announced the closing of a $50 million registered direct financing at a 30% premium. The offering included common stock, pre-funded warrants, and series warrants priced at multiples of the issue price, with gross proceeds totaling approximately $50 million.</p>
<div class="lb-trans"><p>Foghorn Therapeutics Inc. (FHTX) 上漲 4.02% 至 $6.26，漲幅 $0.24。該公司宣佈以 30% 的溢價完成 5000 萬美元的註冊直接融資。此次發行包括普通股、預先融資的認股權證和按發行價格倍數定價的系列認股權證，毛收益總計約 5000 萬美元。</p>
</div><p>Daré Bioscience, Inc. (DARE) edged higher by 1.04% to $1.95, up $0.020. The company did not release any news on Friday, but shares still managed modest after-hours gains.</p>
<div class="lb-trans"><p>Daré Bioscience, Inc. (DARE) 小幅上漲 1.04% 至 $1.95，漲幅 $0.020。該公司週五沒有發佈任何新聞，但股票仍在盤後交易中小幅上漲。</p>
</div><p>Theravance Biopharma, Inc. (TBPH) gained 5.00% to $21.01, adding $1.00. Similar to Daré, the company had no news on Friday, yet shares advanced in extended trading.</p>
<div class="lb-trans"><p>Theravance Biopharma, Inc. (TBPH) 上漲 5.00% 至 $21.01，漲幅 $1.00。與 Daré類似，該公司週五沒有新聞，但股票在延長交易中上漲。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商業新聞</p>
</div>

After-Hours Gainers: ATOS, IBRX, FEMY, FHTX, DARE, TBPH

rttnews

Foghorn Therapeutics

美國制藥 ETF - iShares

ImmunityBio

醫療業 ETF - SPDR

Theravance生物制藥

動態生物技術與基因組 ETF - Invesco

美國醫藥設備 ETF - iShares

Femasys

醫藥突破 ETF - ALPS

基因改革 ETF - ARK

2 倍做多納斯達克生物技術 ETF - ProShares

Invesco Nasdaq Biotechnology ETF

標普生物技術 ETF - SPDR

Dare Bioscience

標普健康醫療設備 ETF - SPDR

醫療業 ETF - Vanguard

標普全球醫療股指數 ETF - iShares

Atossa Therapeutics

納斯達克生物科技指數 ETF - iShares Nasdaq

紐交所高增長板生物技術指數 ETF - First Trust

盤後上漲的股票包括：Atossa Therapeutics, ImmunityBio, Femasys, Foghorn Therapeutics, Dare Bioscience, Theravance BioPharma